Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998;77(3):472–476. doi: 10.1038/bjc.1998.75

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.

G Salama 1, M Miédougé 1, P Rouzaud 1, M A Mauduyt 1, M C Pujazon 1, C Vincent 1, P Carles 1, G Serre 1
PMCID: PMC2151287  PMID: 9472646

Abstract

CYFRA 21-1 assay, measuring cytokeratin 19 fragments, was compared with carcinoembryonic antigen (CEA) assay, as an addition to cytological analysis for the diagnosis of malignant effusions. Both markers were determined with commercial enzyme immunoassays in pleural fluid from 196 patients. Cytological analysis and/or pleural biopsy confirmed the malignant origin of the effusion in 99 patients (76 carcinomas, nine pleural mesotheliomas and 14 non-epithelial malignancies). Effusions were confirmed as benign in 97 patients (33 cardiac failures, 39 infectious diseases--including 12 tuberculosis-- and 25 miscellaneous effusions). Both markers were significantly higher in malignant than in benign effusions. All the patients with non-epithelial malignancies presented CYFRA and CEA values lower than the 95% diagnostic specificity thresholds (100 and 6 ng ml(-1) respectively). The diagnostic sensitivity in the group of carcinomas and mesotheliomas was similar for CYFRA (58.8%) and CEA (64.7%). However, CEA had a significantly higher sensitivity in carcinomas (72.4% vs 55.3%), while CYFRA had a clearly higher sensitivity in mesotheliomas (89.9% vs 0%). Interestingly, 12 out of the 16 malignant effusions with a negative cytology were CEA and/or CYFRA positive. Regarding their high diagnostic sensitivity and their complementarity, CEA and CYFRA appear to be very useful for the diagnosis of malignant pleural effusions when cytology is negative.

Full text

PDF
476

Images in this article

473Figure 1
on p.473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Daste G., Serre G., Mauduyt M. A., Vincent C., Caveriviere P., Soleilhavoup J. P. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions. Cytopathology. 1991;2(1):19–28. doi: 10.1111/j.1365-2303.1991.tb00380.x. [DOI] [PubMed] [Google Scholar]
  2. Doweck I., Barak M., Greenberg E., Uri N., Kellner J., Lurie M., Gruener N. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):177–181. doi: 10.1001/archotol.1995.01890020039009. [DOI] [PubMed] [Google Scholar]
  3. Ferdeghini M., Gadducci A., Prontera C., Castellani C., Annicchiarico C., Gagetti O., Facchini V., Bianchi R. Determination of serum levels of different cytokeratins in patients with uterine malignancies. Anticancer Res. 1994 May-Jun;14(3B):1393–1397. [PubMed] [Google Scholar]
  4. Ferroni P., Szpak C., Greiner J. W., Simpson J. F., Guadagni F., Johnston W. W., Colcher D. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer. 1990 Sep 15;46(3):445–451. doi: 10.1002/ijc.2910460320. [DOI] [PubMed] [Google Scholar]
  5. Hanley J. A., McNeil B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983 Sep;148(3):839–843. doi: 10.1148/radiology.148.3.6878708. [DOI] [PubMed] [Google Scholar]
  6. Harris R. J., Kavuru M. S., Rice T. W., Kirby T. J. The diagnostic and therapeutic utility of thoracoscopy. A review. Chest. 1995 Sep;108(3):828–841. doi: 10.1378/chest.108.3.828. [DOI] [PubMed] [Google Scholar]
  7. Inaba N., Negishi Y., Fukasawa I., Okajima Y., Ota Y., Tanaka K., Matsui H., Iwasaki H., Sudo H., Tanaka N. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumour Biol. 1995;16(6):345–352. doi: 10.1159/000217951. [DOI] [PubMed] [Google Scholar]
  8. Johnston W. W. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985 Aug 15;56(4):905–909. doi: 10.1002/1097-0142(19850815)56:4<905::aid-cncr2820560435>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. LaRocca P. J., Rheinwald J. G. Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. Cancer Res. 1984 Jul;44(7):2991–2999. [PubMed] [Google Scholar]
  10. Loddenkemper R., Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993 Nov;6(10):1544–1555. [PubMed] [Google Scholar]
  11. Mezger J., Lamerz R., Permanetter W. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg. 1990 Dec;100(6):860–866. [PubMed] [Google Scholar]
  12. Molina R., Agusti C., Filella X., Jo J., Joseph J., Giménez N., Ballesta A. M. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol. 1994;15(6):318–325. doi: 10.1159/000217908. [DOI] [PubMed] [Google Scholar]
  13. Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
  14. Nakata B., Chung Y. S., Kato Y., Ogawa M., Ogawa Y., Inui A., Maeda K., Sawada T., Sowa M. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer. 1996 Jun;73(12):1529–1532. doi: 10.1038/bjc.1996.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Parazzi F., Faravelli B., Gallo L., Nosenzo M., Razzetti A., Barone D., Bandelloni R., D'Amore E. Tissue polypeptide antigen (TPA) in pleural effusions. Tumori. 1987 Feb 28;73(1):33–36. doi: 10.1177/030089168707300106. [DOI] [PubMed] [Google Scholar]
  16. Peto J., Hodgson J. T., Matthews F. E., Jones J. R. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995 Mar 4;345(8949):535–539. doi: 10.1016/s0140-6736(95)90462-x. [DOI] [PubMed] [Google Scholar]
  17. Plebani M., Basso D., Navaglia F., De Paoli M., Tommasini A., Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer. 1995 Jul;72(1):170–173. doi: 10.1038/bjc.1995.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pujol J. L., Grenier J., Daurès J. P., Daver A., Pujol H., Michel F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993 Jan 1;53(1):61–66. [PubMed] [Google Scholar]
  19. Romero S., Fernández C., Arriero J. M., Espasa A., Candela A., Martín C., Sánchez-Payá J. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J. 1996 Jan;9(1):17–23. doi: 10.1183/09031936.96.09010017. [DOI] [PubMed] [Google Scholar]
  20. Satoh H., Sumi M., Yagyu H., Ishikawa H., Suyama T., Naitoh T., Saitoh T., Hasegawa S. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology. 1995 May-Jun;52(3):211–214. doi: 10.1159/000227459. [DOI] [PubMed] [Google Scholar]
  21. Senga Y., Kimura G., Hattori T., Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology. 1996 Nov;48(5):703–710. doi: 10.1016/S0090-4295(96)00253-1. [DOI] [PubMed] [Google Scholar]
  22. Stieber P., Hasholzner U., Bodenmüller H., Nagel D., Sunder-Plassmann L., Dienemann H., Meier W., Fateh-Moghadam A. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993 Aug 1;72(3):707–713. doi: 10.1002/1097-0142(19930801)72:3<707::aid-cncr2820720313>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  23. Tokuyama T., Yoneda T., Hamada K., Yoshikawa M., Fu A., Tomoda K., Nakaya M., Narita N., Tamura M., Kitamura K. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Jan;33(1):39–43. [PubMed] [Google Scholar]
  24. Toumbis M., Rasidakis A., Passalidou E., Kalomenidis J., Alchanatis M., Orphanidou D., Jordanoglou J. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res. 1996 Jul-Aug;16(4A):2101–2104. [PubMed] [Google Scholar]
  25. Villena V., López-Encuentra A., Echave-Sustaeta J., Martín-Escribano P., Ortuño-de-Solo B., Estenoz-Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer. 1996 Aug 15;78(4):736–740. doi: 10.1002/(SICI)1097-0142(19960815)78:4<736::AID-CNCR7>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  26. van der Gaast A., Schoenmakers C. H., Kok T. C., Blijenberg B. G., Cornillie F., Splinter T. A. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer. 1994 Mar;69(3):525–528. doi: 10.1038/bjc.1994.95. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES